In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback